Valentina Nekljudova

TL;DR: The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain this paper, however, it is known that pCR is associated with long-term outcome of 6,377 patients with primary breast cancer receiving neoadjuvant anthracycline-taxane-based chemotherapy in seven randomized trials.

TL;DR: Sentinel-lymph-node biopsy is a reliable diagnostic method before neoadjuvant chemotherapy and after systemic treatment or early sentinel-allymph- node biopsy, the procedure has a lower detection rate and a higher false-negative rate compared with sentinel

TL;DR: A large number of patients with previously untreated, non-metastatic, stage II-III, triple-negative breast cancer and HER2-positive breast cancer were enrolled and the proportion of patients who achieved a pathological complete response to carboplatin was analyzed.

TL;DR: Continuation of trastuzumab beyond progression was not associated with increased toxicity and showed a significant improvement in overall response and time to progression compared with capecitabine alone in women with HER-2-positive breast cancer who experienced progression during trastzumab treatment.

TL;DR: The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response among patients with HER2-negative early-stage breast cancer.